Abivax (ADR)
Develops oral obefazimod for ulcerative colitis and Crohn's disease.
$113.67
After-hours close+0.35 (+0.31%)
At close$113.32(−0.86%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Sep 2026 | −$0.96 | — | — |
| May 2026 | −$0.94 | −$0.71 | +23.9% |
| Mar 2026 | −$1.07 | −$1.22 | −14.2% |
| Sep 2025 | −$0.90 | −$0.86 | +4.4% |
| Mar 2025 | −$0.68 | −$1.55 | −128.0% |
The latest year is open to everyone — the 21 quarters behind it read with an account. Sign in | |||
| Nov 2024 | |||
| Apr 2024 | |||
| Jun 2023 | |||
| Dec 2022 | |||
| Jun 2022 | |||
| Dec 2021 | |||
| Jun 2021 | |||
| Dec 2020 | |||
| Jun 2020 | |||
| Dec 2019 | |||
| Jun 2019 | |||
| Dec 2018 | |||
| Jun 2018 | |||
| Dec 2017 | |||
| Jun 2017 | |||
| Dec 2016 | |||
| Jun 2016 | |||
| Dec 2015 | |||
| Jun 2015 | |||
| Dec 2014 | |||
| Jun 2014 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Sep 21, 2026 | −$0.96 | — | — | $778.5K | — | — |
| May 22, 2026 | −$0.94 | −$0.71 | +23.9% | $401.1K | $1.5M | +277.3% |
| Mar 23, 2026 | −$1.07 | −$1.22 | −14.2% | $1.8M | $512.2K | −71.6% |
| Sep 8, 2025 | −$0.90 | −$0.86 | +4.4% | $1.4M | $2.4M | +70.6% |
| Mar 24, 2025 | −$0.68 | −$1.55 | −128.0% | $3.1M | $7.7M | +146.2% |
The latest year is open to everyone — the 21 quarters behind it read with an account. Sign in | ||||||
| Nov 7, 2024 | ||||||
| Apr 2, 2024 | ||||||
| Jun 30, 2023 | ||||||
| Dec 31, 2022 | ||||||
| Jun 30, 2022 | ||||||
| Dec 31, 2021 | ||||||
| Jun 30, 2021 | ||||||
| Dec 31, 2020 | ||||||
| Jun 30, 2020 | ||||||
| Dec 31, 2019 | ||||||
| Jun 30, 2019 | ||||||
| Dec 31, 2018 | ||||||
| Jun 30, 2018 | ||||||
| Dec 31, 2017 | ||||||
| Jun 30, 2017 | ||||||
| Dec 31, 2016 | ||||||
| Jun 30, 2016 | ||||||
| Dec 31, 2015 | ||||||
| Jun 30, 2015 | ||||||
| Dec 31, 2014 | ||||||
| Jun 30, 2014 | ||||||